echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Zhejiang Jingxin Pharmaceuticals received CFDA approval issued by the heavy lig litadine kabaratin capsule drug registration approval

    Zhejiang Jingxin Pharmaceuticals received CFDA approval issued by the heavy lig litadine kabaratin capsule drug registration approval

    • Last Update: 2020-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    yesterday, Zhejiang Jing
    new drug(limited shares
    of the company
    (issued a notice that the company has received the State Food and Drug Administration approved the issuance of heavy lignin kabaratin capsules (specifications 1.5mg and 3.0mg)drug(registered approval, approval document number is the national drug code H20183124 and the national drug code H20183125)on heavy lig litanacinAccording to data, heavy lig litaline kabaratin is a first-linedrugdeveloped by Novartis of Spain for the treatment of mild, moderate Alzheimer's dementia (has been on the market in China for many years)Compared to similar drugsthe treatment index of matsalitin is high, and the use of antipsychotic drugs and complementary statins can be significantly reduced during treatment, the clinical efficacy is significant, and has broad application prospects in the field of Alzheimer's dementia treatmentAt present, Jingxin Pharmaceuticals is the firstmanufacturer in China to obtain the batch of heavy lig-satric acid kabaratin capsule production(and the company's first treatment for Alzheimer's dementia drugs, this approval will have a positive impact on the company's pharmaceutical business.)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.